IL17A and myeloid sarcoma: Of interest, we noticed a dominant Th17 cytokine profile in this group of MS patients as revealed by increased expression of Il17a, Il17f, Il21, IL23r and Rorc (Fig. 6e; Supplementary Fig. 9B).